Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0BL849
Fri, 12.05.2023
Vita 34 AG
Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
Approval by responsible authorities and ethics committee granted
Recruitment of the first patient imminent
Completion of Phase I expected by the end of 2023
Leipzig, 12 May 2023 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third lar [ … ]
Fri, 12.05.2023
Vita 34 AG
Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
Approval by responsible authorities and ethics committee granted
Recruitment of the first patient imminent
Completion of Phase I expected by the end of 2023
Leipzig, 12 May 2023 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third lar [ … ]
Sun, 30.04.2023
Vita 34 AG
Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Group revenue of EUR 68.9 million 142.6 percent above previous year after merger with PBKM FamiCord (Guidance: EUR 65 to 72 million)
EBITDA of EUR -3.6 million, mostly due to one-off effects under IFRS-15 (Guidance: EUR -6.0 to -3.0 mi [ … ]
Sun, 30.04.2023
Vita 34 AG
Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
Group revenue of EUR 68.9 million 142.6 percent above previous year after merger with PBKM FamiCord (Guidance: EUR 65 to 72 million)
EBITDA of EUR -3.6 million, mostly due to one-off effects under IFRS-15 (Guidance: EUR -6.0 to -3.0 mi [ … ]
Tue, 25.04.2023
Vita 34 AG
Vita 34 AG publishes outlook for the 2023 financial year
Leipzig, April 25, 2023 - In the context of the preparation of the consolidated financial statements 2022, the Management Board today approved the outlook report on the expected business development of Vita 34 AG in the 2023 financial year. Based on current analyst estimates, the Management [ … ]
Tue, 25.04.2023
Vita 34 AG
Vita 34 AG publishes outlook for the 2023 financial year
Leipzig, April 25, 2023 - In the context of the preparation of the consolidated financial statements 2022, the Management Board today approved the outlook report on the expected business development of Vita 34 AG in the 2023 financial year. Based on current analyst estimates, the Management [ … ]
Thu, 06.04.2023
Vita 34 AG
2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
Leipzig, 6 April 2023 - As part of the 2022 audit of the consolidated financial statements, the Group's auditor PwC today materially completed the impairment test of goodwill. This results in a non-cash impairment totaling EUR 13.8 million, which is largely based o [ … ]
Thu, 06.04.2023
Vita 34 AG
2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
Leipzig, 6 April 2023 - As part of the 2022 audit of the consolidated financial statements, the Group's auditor PwC today materially completed the impairment test of goodwill. This results in a non-cash impairment totaling EUR 13.8 million, which is largely based o [ … ]
Tue, 22.11.2022
Vita 34 AG
Vita 34 benefits from increasing normalization in its core business in the third quarter
Revenues for the first nine months rose to EUR 50.8 million; business development gains further momentum in the third quarter
EBITDA of EUR -1.6 million in the first nine months below previous year due to continued investments in the new activities, but alrea [ … ]
Tue, 22.11.2022
Vita 34 AG
Vita 34 benefits from increasing normalization in its core business in the third quarter
Revenues for the first nine months rose to EUR 50.8 million; business development gains further momentum in the third quarter
EBITDA of EUR -1.6 million in the first nine months below previous year due to continued investments in the new activities, but alrea [ … ]